PMC:7600245 / 57960-58680 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T253","span":{"begin":152,"end":165},"obj":"Body_part"},{"id":"T254","span":{"begin":607,"end":610},"obj":"Body_part"}],"attributes":[{"id":"A253","pred":"fma_id","subj":"T253","obj":"http://purl.org/sig/ont/fma/fma83030"},{"id":"A254","pred":"fma_id","subj":"T254","obj":"http://purl.org/sig/ont/fma/fma67095"}],"text":"4.9. Plitidepsin (Aplidin)\nIt is a cyclic depsipeptide natural product (Figure S5) that is extracted from Aplidium albicans [186]. It is used for acute lymphoblastic leukemia and, with dexamethasone, for patients with refractory and relapsed multiple myeloma [187]. Recently, the molecule was reported to have in vitro nanomolar potency against the human coronavirus 229E [188]. The mechanism is thought to be similar to its anticancer activity, i.e., targeting eukaryotic translation elongation factor 1-α1, which has been reported to play an unexpected role in the replication and pathogenesis of various RNA viruses [189,190]. The drug is being tested in phase 1 trial in patients with COVID-19 (NCT04382066; n = 27)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T253","span":{"begin":146,"end":174},"obj":"Disease"},{"id":"T254","span":{"begin":152,"end":174},"obj":"Disease"},{"id":"T255","span":{"begin":166,"end":174},"obj":"Disease"},{"id":"T256","span":{"begin":242,"end":258},"obj":"Disease"},{"id":"T257","span":{"begin":251,"end":258},"obj":"Disease"},{"id":"T258","span":{"begin":689,"end":697},"obj":"Disease"}],"attributes":[{"id":"A253","pred":"mondo_id","subj":"T253","obj":"http://purl.obolibrary.org/obo/MONDO_0004967"},{"id":"A254","pred":"mondo_id","subj":"T254","obj":"http://purl.obolibrary.org/obo/MONDO_0001018"},{"id":"A255","pred":"mondo_id","subj":"T255","obj":"http://purl.obolibrary.org/obo/MONDO_0005059"},{"id":"A256","pred":"mondo_id","subj":"T256","obj":"http://purl.obolibrary.org/obo/MONDO_0009693"},{"id":"A257","pred":"mondo_id","subj":"T257","obj":"http://purl.obolibrary.org/obo/MONDO_0005170"},{"id":"A258","pred":"mondo_id","subj":"T258","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"4.9. Plitidepsin (Aplidin)\nIt is a cyclic depsipeptide natural product (Figure S5) that is extracted from Aplidium albicans [186]. It is used for acute lymphoblastic leukemia and, with dexamethasone, for patients with refractory and relapsed multiple myeloma [187]. Recently, the molecule was reported to have in vitro nanomolar potency against the human coronavirus 229E [188]. The mechanism is thought to be similar to its anticancer activity, i.e., targeting eukaryotic translation elongation factor 1-α1, which has been reported to play an unexpected role in the replication and pathogenesis of various RNA viruses [189,190]. The drug is being tested in phase 1 trial in patients with COVID-19 (NCT04382066; n = 27)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T583","span":{"begin":33,"end":34},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T584","span":{"begin":79,"end":81},"obj":"http://purl.obolibrary.org/obo/CLO_0008933"},{"id":"T585","span":{"begin":349,"end":354},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T586","span":{"begin":436,"end":444},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T587","span":{"begin":462,"end":472},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_2759"},{"id":"T588","span":{"begin":515,"end":518},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T589","span":{"begin":611,"end":618},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T590","span":{"begin":648,"end":654},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T591","span":{"begin":716,"end":718},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"}],"text":"4.9. Plitidepsin (Aplidin)\nIt is a cyclic depsipeptide natural product (Figure S5) that is extracted from Aplidium albicans [186]. It is used for acute lymphoblastic leukemia and, with dexamethasone, for patients with refractory and relapsed multiple myeloma [187]. Recently, the molecule was reported to have in vitro nanomolar potency against the human coronavirus 229E [188]. The mechanism is thought to be similar to its anticancer activity, i.e., targeting eukaryotic translation elongation factor 1-α1, which has been reported to play an unexpected role in the replication and pathogenesis of various RNA viruses [189,190]. The drug is being tested in phase 1 trial in patients with COVID-19 (NCT04382066; n = 27)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T87184","span":{"begin":18,"end":25},"obj":"Chemical"},{"id":"T98196","span":{"begin":42,"end":54},"obj":"Chemical"},{"id":"T53858","span":{"begin":79,"end":81},"obj":"Chemical"},{"id":"T25151","span":{"begin":185,"end":198},"obj":"Chemical"},{"id":"T51216","span":{"begin":280,"end":288},"obj":"Chemical"},{"id":"T82308","span":{"begin":634,"end":638},"obj":"Chemical"}],"attributes":[{"id":"A31481","pred":"chebi_id","subj":"T87184","obj":"http://purl.obolibrary.org/obo/CHEBI_90205"},{"id":"A63069","pred":"chebi_id","subj":"T98196","obj":"http://purl.obolibrary.org/obo/CHEBI_23643"},{"id":"A44787","pred":"chebi_id","subj":"T53858","obj":"http://purl.obolibrary.org/obo/CHEBI_29386"},{"id":"A3343","pred":"chebi_id","subj":"T25151","obj":"http://purl.obolibrary.org/obo/CHEBI_41879"},{"id":"A12474","pred":"chebi_id","subj":"T51216","obj":"http://purl.obolibrary.org/obo/CHEBI_25367"},{"id":"A40814","pred":"chebi_id","subj":"T82308","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"4.9. Plitidepsin (Aplidin)\nIt is a cyclic depsipeptide natural product (Figure S5) that is extracted from Aplidium albicans [186]. It is used for acute lymphoblastic leukemia and, with dexamethasone, for patients with refractory and relapsed multiple myeloma [187]. Recently, the molecule was reported to have in vitro nanomolar potency against the human coronavirus 229E [188]. The mechanism is thought to be similar to its anticancer activity, i.e., targeting eukaryotic translation elongation factor 1-α1, which has been reported to play an unexpected role in the replication and pathogenesis of various RNA viruses [189,190]. The drug is being tested in phase 1 trial in patients with COVID-19 (NCT04382066; n = 27)."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T99","span":{"begin":473,"end":495},"obj":"http://purl.obolibrary.org/obo/GO_0006414"},{"id":"T100","span":{"begin":473,"end":484},"obj":"http://purl.obolibrary.org/obo/GO_0006412"},{"id":"T101","span":{"begin":583,"end":595},"obj":"http://purl.obolibrary.org/obo/GO_0009405"}],"text":"4.9. Plitidepsin (Aplidin)\nIt is a cyclic depsipeptide natural product (Figure S5) that is extracted from Aplidium albicans [186]. It is used for acute lymphoblastic leukemia and, with dexamethasone, for patients with refractory and relapsed multiple myeloma [187]. Recently, the molecule was reported to have in vitro nanomolar potency against the human coronavirus 229E [188]. The mechanism is thought to be similar to its anticancer activity, i.e., targeting eukaryotic translation elongation factor 1-α1, which has been reported to play an unexpected role in the replication and pathogenesis of various RNA viruses [189,190]. The drug is being tested in phase 1 trial in patients with COVID-19 (NCT04382066; n = 27)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T61","span":{"begin":146,"end":174},"obj":"Phenotype"},{"id":"T62","span":{"begin":242,"end":258},"obj":"Phenotype"}],"attributes":[{"id":"A61","pred":"hp_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/HP_0006721"},{"id":"A62","pred":"hp_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/HP_0006775"}],"text":"4.9. Plitidepsin (Aplidin)\nIt is a cyclic depsipeptide natural product (Figure S5) that is extracted from Aplidium albicans [186]. It is used for acute lymphoblastic leukemia and, with dexamethasone, for patients with refractory and relapsed multiple myeloma [187]. Recently, the molecule was reported to have in vitro nanomolar potency against the human coronavirus 229E [188]. The mechanism is thought to be similar to its anticancer activity, i.e., targeting eukaryotic translation elongation factor 1-α1, which has been reported to play an unexpected role in the replication and pathogenesis of various RNA viruses [189,190]. The drug is being tested in phase 1 trial in patients with COVID-19 (NCT04382066; n = 27)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T436","span":{"begin":0,"end":4},"obj":"Sentence"},{"id":"T437","span":{"begin":5,"end":26},"obj":"Sentence"},{"id":"T438","span":{"begin":27,"end":130},"obj":"Sentence"},{"id":"T439","span":{"begin":131,"end":265},"obj":"Sentence"},{"id":"T440","span":{"begin":266,"end":378},"obj":"Sentence"},{"id":"T441","span":{"begin":379,"end":629},"obj":"Sentence"},{"id":"T442","span":{"begin":630,"end":720},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"4.9. Plitidepsin (Aplidin)\nIt is a cyclic depsipeptide natural product (Figure S5) that is extracted from Aplidium albicans [186]. It is used for acute lymphoblastic leukemia and, with dexamethasone, for patients with refractory and relapsed multiple myeloma [187]. Recently, the molecule was reported to have in vitro nanomolar potency against the human coronavirus 229E [188]. The mechanism is thought to be similar to its anticancer activity, i.e., targeting eukaryotic translation elongation factor 1-α1, which has been reported to play an unexpected role in the replication and pathogenesis of various RNA viruses [189,190]. The drug is being tested in phase 1 trial in patients with COVID-19 (NCT04382066; n = 27)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1804","span":{"begin":462,"end":507},"obj":"Gene"},{"id":"1805","span":{"begin":204,"end":212},"obj":"Species"},{"id":"1806","span":{"begin":349,"end":371},"obj":"Species"},{"id":"1807","span":{"begin":675,"end":683},"obj":"Species"},{"id":"1808","span":{"begin":106,"end":114},"obj":"Chemical"},{"id":"1809","span":{"begin":185,"end":198},"obj":"Chemical"},{"id":"1810","span":{"begin":42,"end":54},"obj":"Disease"},{"id":"1811","span":{"begin":146,"end":174},"obj":"Disease"},{"id":"1812","span":{"begin":251,"end":258},"obj":"Disease"},{"id":"1813","span":{"begin":689,"end":697},"obj":"Disease"}],"attributes":[{"id":"A1804","pred":"tao:has_database_id","subj":"1804","obj":"Gene:1915"},{"id":"A1805","pred":"tao:has_database_id","subj":"1805","obj":"Tax:9606"},{"id":"A1806","pred":"tao:has_database_id","subj":"1806","obj":"Tax:11137"},{"id":"A1807","pred":"tao:has_database_id","subj":"1807","obj":"Tax:9606"},{"id":"A1809","pred":"tao:has_database_id","subj":"1809","obj":"MESH:D003907"},{"id":"A1811","pred":"tao:has_database_id","subj":"1811","obj":"MESH:D054198"},{"id":"A1812","pred":"tao:has_database_id","subj":"1812","obj":"MESH:D009101"},{"id":"A1813","pred":"tao:has_database_id","subj":"1813","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"4.9. Plitidepsin (Aplidin)\nIt is a cyclic depsipeptide natural product (Figure S5) that is extracted from Aplidium albicans [186]. It is used for acute lymphoblastic leukemia and, with dexamethasone, for patients with refractory and relapsed multiple myeloma [187]. Recently, the molecule was reported to have in vitro nanomolar potency against the human coronavirus 229E [188]. The mechanism is thought to be similar to its anticancer activity, i.e., targeting eukaryotic translation elongation factor 1-α1, which has been reported to play an unexpected role in the replication and pathogenesis of various RNA viruses [189,190]. The drug is being tested in phase 1 trial in patients with COVID-19 (NCT04382066; n = 27)."}